Submit your email to push it up the queue
Bardy Diagnostics, Inc., commonly referred to as BardyDx, is a pioneering company headquartered in the United States, specialising in innovative cardiac monitoring solutions. Founded in 2015, BardyDx has rapidly established itself within the medical technology industry, focusing on advanced diagnostic tools that enhance patient care and streamline clinical workflows. The company is renowned for its flagship product, the BardyDx Cardiac Patch, which offers continuous, non-invasive monitoring of cardiac activity. This unique device stands out for its ability to provide comprehensive data while ensuring patient comfort. With a commitment to improving cardiovascular health, BardyDx has achieved significant milestones, including regulatory approvals and partnerships that bolster its market position. As a leader in cardiac diagnostics, BardyDx continues to drive advancements that benefit both healthcare providers and patients alike.
How does Bardy Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bardy Diagnostics, Inc.'s score of 27 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bardy Diagnostics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Baxter International Inc., which may influence its climate commitments and emissions reporting. As of now, Bardy Diagnostics has not established any documented reduction targets or initiatives under the Science Based Targets initiative (SBTi). Additionally, there are no climate pledges or specific reduction initiatives reported. Emissions data and climate commitments may be inherited from its parent company, Baxter International Inc., which operates at a cascade level of three. This means that while Bardy Diagnostics may not have direct emissions data, it is part of a larger corporate family that may have its own climate strategies and performance metrics. In summary, Bardy Diagnostics, Inc. is currently in the process of aligning its climate commitments with its parent company's initiatives, but specific emissions data and reduction targets are not available at this time.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2024 | |
---|---|---|---|
Scope 1 | - | 00,000,000 | 0,000,000,000 |
Scope 2 | 43,469,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | 0,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bardy Diagnostics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.